Tolemy Bio Raises €1.4M for AI Lab Data Platform

In a significant development for the biopharmaceutical research sector, Tolemy Bio has successfully closed a €1.4 million pre-seed funding round. This capital infusion is earmarked to advance the company's mission of transforming disparate laboratory experimental data into actionable, AI-ready intelligence. The funding was spearheaded by Norrsken Evolve, with crucial participation from Big Sur Ventures, JME Ventures, Masia, and a newly established, undisclosed UK-based stealth fund. This investment underscores a growing recognition of the critical need for robust data infrastructure in accelerating drug discovery and development.

The core of Tolemy Bio's offering is its proprietary platform, Orbit. Designed to integrate seamlessly with existing laboratory instrumentation and software, Orbit acts as a central hub, consolidating fragmented experimental outputs from spreadsheets, equipment logs, and various digital files into a unified, AI-native workspace. A secondary component, termed a 'virtual cell,' aims to provide researchers with an intuitive, high-level visualization of cellular responses to environmental stimuli, thereby enhancing experimental oversight and strategic planning.

This funding arrives at a pivotal juncture for the biopharma industry, where the adoption of artificial intelligence is a top priority. Industry reports indicate that while a substantial majority of biopharma firms (up to 70%) identify AI as a key investment area, a significant gap exists in practical implementation, with fewer than 3% of smaller entities considering themselves AI-ready. Tolemy Bio's founders, Alex Ward and Caelan Anderson, who previously encountered these data integration challenges at cultivated meat startup Vow, are addressing this infrastructure deficit directly.

“The sheer volume of experimental data generated daily is immense, yet its potential as reusable intelligence is frequently unrealized due to fragmented systems,” stated Alex Ward, Co-Founder and CEO of Tolemy Bio. The company's strategic focus on building foundational data infrastructure, rather than simply applying AI to existing workflows, resonated strongly with investors. Rebecka Löthman Rydå, General Partner at Norrsken Evolve, commented that Tolemy Bio is “building the infrastructure needed to make complex therapies more understandable and controllable.”

Tolemy Bio's innovative approach has already garnered early traction, with organizations such as MIT, the University of Cambridge, MFX, and Anthony Nolan participating in a phased rollout of the Orbit platform. Furthermore, the company has forged a strategic partnership with California-based media supplier GeminiBio to co-develop aiMOS. This collaborative product targets a specific pain point in cell therapy manufacturing: enhancing performance and consistency while managing production costs.

The newly acquired capital will be instrumental in bolstering Tolemy Bio's capabilities in data generation, machine learning development, and core engineering functions. While officially headquartered in Cambridge, the company intends to operate primarily from Barcelona. This funding round positions Tolemy Bio to make a substantial impact on the efficiency and effectiveness of biological research and development, a sector ripe for digital transformation.